Treatment of Chronic Urticaria

Immunology and Allergy Clinics of North America

Volumn 34, Issue 1, 2014, Pages 105-116

  Asero, Riccardo ^a   Tedeschi, Alberto ^b   Cugno, Massimo ^c  

^a Ospedale 21   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Antihistamines; Chronic urticaria; Ciclosporin; Corticosteroids; Omalizumab; Therapy

Indexed keywords

ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BILASTINE; CETIRIZINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; DESLORATADINE; EBASTINE; FEXOFENADINE; HEPARIN; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR AGONIST; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; LEVOCETIRIZINE; METHOTREXATE; MIZORIBINE; MONTELUKAST; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OMALIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TACROLIMUS; UNINDEXED DRUG; ZAFIRLUKAST;

ANAPHYLAXIS; ANEMIA; ANOREXIA; ASEPTIC MENINGITIS; BLOOD DYSCRASIA; BLOOD TOXICITY; CHRONIC URTICARIA; CLINICAL PRACTICE; DIABETES MELLITUS; DISEASE SEVERITY; DRESS SYNDROME; DRUG COST; DRUG DOSE REDUCTION; DRUG RESPONSE; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; METHEMOGLOBINEMIA; NAUSEA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RASH; RETINOPATHY; REVIEW; TREATMENT INDICATION; VOMITING;

ANTIHISTAMINES; CHRONIC URTICARIA; CICLOSPORIN; CORTICOSTEROIDS; OMALIZUMAB; THERAPY;

CHRONIC DISEASE; HUMANS; URTICARIA;

EID: 84887992112     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2013.09.013     Document Type: Review

References (101)

1. Greaves M.W., Tan K.T. Chronic urticaria: recent advances. Clin Rev Allergy Immunol 2007, 33:134-143.
2. Gaig P., Olona M., Munoz Lejarazu D., et al. Epidemiology of urticaria in Spain. JInvestig Allergol Clin Immunol 2004, 14:214-220.
3. O'Donnell B.F., Lawlor F., Simpson J., et al. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136:197-201.
4. Grattan C.E., Wallington T.B., Warin R.P., et al. Aserological mediator in chronic idiopathic urticaria: a clinical, immunological and histological evaluation. Br J Dermatol 1986, 114:583-590.
5. Grattan C.E., Francis D.M., Hide M., et al. Detection of circulating histamine releasing autoantibodies with functional properties of anti-IgE in chronic urticaria. Clin Exp Allergy 1991, 21:695-704.
6. Hide M., Francis D.M., Grattan C.E., et al. Autoantibodies against the high affinity IgE receptor as a cause of histamine release in chronic urticaria. NEngl J Med 1993, 328:1599-1604.
7. Tedeschi A., Asero R., Lorini M., et al. Plasma levels of matrix metalloproteinase-9 in chronic urticaria patients correlate with disease severity and C-reactive protein but not with circulating histamine-releasing factors. Clin Exp Allergy 2010, 40:875-881.
8. Asero R., Tedeschi A., Riboldi P., et al. Plasma of patients with chronic urticaria shows signs of thrombin generation, and its intradermal injection causes wheal-and-flare reactions much more frequently than autologous serum. JAllergy Clin Immunol 2006, 117:1113-1117.
9. Cugno M., Marzano A.V., Asero R., et al. Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. Intern Emerg Med 2010, 5:97-101.
10. Zuberbier T., Bindslev-Jensen C., Canonica G.W., et al. EAACI/GA2LEN guideline: management of urticaria. Allergy 2006, 61:321-331.
11. Powell R.J., Du Toit G.L., Siddique N., British Society for Allergy and Clinical Immunology (BSACI), et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007, 37:631-650.
12. Tedeschi A., Girolomoni G., Asero R., AAITO Committee for Chronic Urticaria and Pruritus Guidelines AAITO Position paper. Chronic urticaria: diagnostic workup and treatment. Eur Ann Allergy Clin Immunol 2007, 39:225-231.
13. Zuberbier T., Asero R., Bindslev-Jensen C., Dermatology Section of the European Academy of Allergology and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, World Allergy Organization, et al. EAACI/GA2LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443.
14. Sánchez-Borges M., Asero R., Ansotegui I.J., WAO Scientific and Clinical Issues Council, et al. Diagnosis and treatment of urticaria and angioedema: a worldwide perspective. World Allergy Organ J 2012, 5(11):125-147.
15. Zuberbier T, Aberer W, Asero R, etal. The EAACI/GA2LEN/EDF/AAAAI/WAO/Guideline for the definition, classification, diagnosis and management of Urticaria. The 2013 revision and update. Allergy, in press.
16. Grant J.A., Danielson L., Rihoux J.P., et al. Adouble-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine-induced wheal and flare response for 24 h in healthy male subjects. Allergy 1999, 54:700-707.
17. Grant J.A., Riethuisen J.M., Moulaert B., et al. Adouble-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002, 88:190-197.
18. Frossard N., Strolin-Benedetti M., Purohit A., et al. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol 2008, 65:172-179.
19. Handa S., Dogra S., Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. JDermatolog Treat 2004, 15:55-57.
20. Potter P.C., Kapp A., Maurer M., et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009, 64:596-604.
21. Clough G.F., Boutsiouki P., Church M.K. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 2001, 56:985-988.
22. Popov T.A., Dumitrascu D., Bachvarova A., et al. Acomparison of levocetirizine and desloratadine in the histamine-induced wheal and flare response in human skin invivo. Inflamm Res 2006, 55:241-244.
23. Zuberbier T., Oanta A., Bogacka E., Bilastine International Working Group, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010, 65:516-528.
24. Maiti R., Jaida J., Raghavendra B.N., et al. Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. JDrugs Dermatol 2011, 10:1444-1450.
25. Hindmarch I., Johnson S., Meadows R., et al. The acute and sub-chronic effects of levocetirizine, cetirizine, lotatadine, promethazine and placebo on cognitive function, psychomotor performance, and wheal and flare. Curr Med Res Opin 2001, 17:241-255.
26. Curran M.P., Scott L.J., Perry C.M. Cetirizine: a review of its use in allergic disorders. Drugs 2004, 15:55-57.
27. Grant J.A., Bernstein D.I., Buckley C.E., et al. Double-blind comparison of terfenadine, chlorpheniramine, and placebo in the treatment of chronic idiopathic urticaria. JAllergy Clin Immunol 1998, 81:574-579.
28. Monroe E.W. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Clin Ther 1992, 14:17-21.
29. Breneman D.L. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996, 30:1075-1079.
30. Shamsi Z., Hindmarch I. Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000, 15(S1):S3-S30.
31. Siebenhaar F., Degener F., Zuberbier T., et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. JAllergy Clin Immunol 2009, 123:672-679.
32. Kameyoshi Y., Tanaka T., Mihara S., et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007, 157:803-804.
33. Staevska M., Popov T.A., Kralimarkova T., et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. JAllergy Clin Immunol 2010, 125:676-682.
34. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007, 32:34-38.
35. Monroe E.W., Cohen S.H., Kalbfleisch J., et al. Combined H1 and H2 antihistamine therapy in chronic urticaria. Arch Dermatol 1981, 117:404-407.
36. Bleehen S.S., Thomas S.E., Greaves M.W., et al. Cimetidine and chlorpheniramine in the treatment of chronic idiopathic urticaria: a multi-centre randomized double-blind study. Br J Dermatol 1987, 117:81-88.
37. Paul E., Bodeker R.H. Treatment of chronic urticaria with terfenadine and ranitidine. A randomized double-blind study in 45 patients. Eur J Clin Pharmacol 1986, 31:277-280.
38. Sharpe G.R., Shuster R. In dermographic urticaria H2 receptor antagonists have a small but therapeutically irrelevant additional effect compared with H1 antagonists alone. Br J Dermatol 1993, 129:575-579.
39. Asero R., Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. JInvestig Allergol Clin Immunol 2010, 20:386-390.
40. Tedeschi A., Suli C., Lorini M., et al. Successful treatment of chronic urticaria. Allergy 2000, 55:1097-1098.
41. Asero R., Tedeschi A., Lorini M. Leukotriene receptor antagonists in chronic urticaria. Allergy 2001, 56:456-457.
42. Bagenstose S.E., Levin L., Bernstein J.A. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. JAllergy Clin Immunol 2004, 113:134-140.
43. Di Lorenzo G., Pacor M.L., Mansueto P., et al. Randomized placebo-controlled trial comparing desloratadine and montelukast in monotherapy and desloratadine plus montelukast in combined therapy for chronic idiopathic urticaria. JAllergy Clin Immunol 2004, 114:619-625.
44. Nettis E., Colanardi M.C., Paradiso M.T., et al. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2004, 34:1401-1407.
45. Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. JAllergy Clin Immunol 2002, 110:484-488.
46. Pacor M.L., Di Lorenzo G., Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001, 31:1607-1614.
47. Reimers A., Pichler C., Helbling A., et al. Zafirlukast has no beneficial effects in the treatment of chronic urticaria. Clin Exp Allergy 2002, 32:1763-1768.
48. Boehm I., Bauer R., Bieber T. Urticaria treated with dapsone. Allergy 1999, 54:765-766.
49. Cassano N., D'Argento V., Filotico R., et al. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005, 85:254-255.
50. Engin B., Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. JEur Acad Dermatol Venereol 2008, 22:481-486.
51. Jaffer A.M. Sulfasalazine in the treatment of corticosteroid-dependent chronic idiopathic urticaria. JAllergy Clin Immunol 1991, 88:964-965.
52. Engler R.J., Squire E., Benson P. Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Ann Allergy Asthma Immunol 1995, 74:155-159.
53. Hartmann K., Hani N., Hinrichs R., et al. Successful sulfasalazine treatment of severe chronic idiopathic urticaria associated with pressure urticaria. Acta Derm Venereol 2001, 81:71.
54. McGirt L.Y., Vasagar K., Gober L.M., et al. Successful treatment of recalcitrant chronic idiopathic urticaria with sulfasalazine. Arch Dermatol 2006, 142:1337-1342.
55. Reeves G.E., Boyle M.J., Bonfield J., et al. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J 2004, 34:182-186.
56. Fradin M.S., Ellis C.N., Goldfarb M.T., et al. Oral cyclosporine for severe chronic idiopathic urticaria and angioedema. JAm Acad Dermatol 1991, 25(6 Pt 1):1065-1067.
57. Toubi E., Blant A., Kessel A., et al. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 1997, 52:312-316.
58. Serhat Inaloz H., Ozturk S., Akcali C., et al. Low-dose and short-term cyclosporine treatment in patients with chronic idiopathic urticaria: a clinical and immunological evaluation. JDermatol 2008, 35:276-282.
59. Grattan C.E., O'Donnell B.F., Francis D.M., et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000, 143:365-372.
60. Di Gioacchino M., Di Stefano F., Cavallucci E., et al. Treatment of chronic idiopathic urticaria and positive autologous serum skin test with cyclosporine: clinical and immunological evaluation. Allergy Asthma Proc 2003, 24:285-290.
61. Baskan E.B., Tunali S., Turker T., et al. Comparison of short- and long-term cyclosporine A therapy in chronic idiopathic urticaria. JDermatolog Treat 2004, 15:164-168.
62. Vena G.A., Cassano N., Colombo D., Neo-I-30 Study Group, et al. Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. JAm Acad Dermatol 2006, 55:705-709.
63. Kessel A., Toubi E. Cyclosporine-A in severe chronic urticaria: the option for long-term therapy. Allergy 2010, 65:1478-1482.
64. Kessel A., Bamberger E., Toubi E. Tacrolimus in the treatment of severe chronic idiopathic urticaria: an open-label prospective study. JAm Acad Dermatol 2005, 52:145-148.
65. Tedeschi A., Airaghi L., Lorini M., et al. Chronic urticaria: a role for newer immunomodulatory drugs?. Am J Clin Dermatol 2003, 4:297-305.
66. Perez A., Woods A., Grattan C.E. Methotrexate: a useful steroid-sparing agent in recalcitrant chronic urticaria. Br J Dermatol 2010, 162:191-194.
67. Sagi L., Solomon M., Baum S., et al. Evidence for methotrexate as a useful treatment for steroid-dependent chronic urticaria. Acta Derm Venereol 2011, 91:303-306.
68. Bernstein J.A., Garramone S.M., Lower E.G. Successful treatment of autoimmune chronic idiopathic urticaria with intravenous cyclophosphamide. Ann Allergy Asthma Immunol 2002, 89:212-214.
69. Asero R. Oral cyclophosphamide in a case of cyclosporin and steroid-resistant chronic urticaria showing autoreactivity on autologous serum skin testing. Clin Exp Dermatol 2005, 30:582-583.
70. Tedeschi A. Paradoxical exacerbation of chronic urticaria by H1-antihistamines and montelukast. Eur Ann Allergy Clin Immunol 2009, 41:187-189.
71. Shahar E., Bergman R., Guttman-Yassky E., et al. Treatment of severe chronic idiopathic urticaria with oral mycophenolate mofetil in patients not responding to antihistamines and/or corticosteroids. Int J Dermatol 2006, 45:1224-1227.
72. Zimmerman A.B., Berger E.M., Elmariah S.B., et al. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: Experience in 19 patients. JAm Acad Dermatol 2012, 66:767-770.
73. Hashimoto T., Kawakami T., Ishii N., et al. Mizoribine treatment for antihistamine-resistant chronic autoimmune urticaria. Dermatol Ther 2012, 25:379-381.
74. Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. JAllergy Clin Immunol 2006, 117:1415-1418.
75. Spector S.L., Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-193.
76. Kaplan A.P., Joseph K., Maykut R.J., et al. Treatment of chronic autoimmune urticaria with omalizumab. JAllergy Clin Immunol 2008, 122:569-573.
77. Dreyfus D.H. Observations on the mechanism of omalizumab as a steroid-spating agent in autoimmune or chronic idiopathic urticaria and angioedema. Ann Allergy Asthma Immunol 2008, 100:624-625.
78. Godse K.V. Omalizumab in severe chronic urticaria. Indian J Dermatol Venereol Leprol 2008, 74:157-158.
79. Vestergaard C., Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010, 90:443-444.
80. Ferrer M., Gamboa P., Sanz M.L., et al. Omalizumab is effective in nonautoimmune urticaria. JAllergy Clin Immunol 2011, 127:1300-1302.
81. Maurer M., Altrichter S., Bieber T., et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. JAllergy Clin Immunol 2011, 128:202-209.
82. Saini S., Rosen K.E., Hsieh H.J., et al. Arandomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. JAllergy Clin Immunol 2011, 128:567-573.
83. Maurer M., Rosén K., Hsieh H.J., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. NEngl J Med 2013, 368:924-935.
84. Kaplan A., Ledford D., Ashby M., et al. Omalizumab in chronic idiopathic/spontaneous urticaria patients symptomatic despite standard combination therapy. JAllergy Clin Immunol 2013, 132:101-109.
85. O'Donnell B.F., Barr R.M., Kobza Black A., et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998, 138:101-106.
86. Pereira C., Tavares B., Carrapatoso I., et al. Low-dose intravenous gammaglobulin in the treatment of severe autoimmune urticaria. Eur Ann Allergy Clin Immunol 2007, 39:237-242.
87. Klote M.M., Nelson M.R., Engler R.J. Autoimmune urticaria response to high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2005, 94:307-308.
88. Wetter D.A., Davis M.D., Yiannias J.A., et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005, 80:41-47.
89. Asero R. Are IVIG for chronic unremitting urticaria effective?. Allergy 2000, 55:1099-1100.
90. Arkwright P.D. Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria. JAllergy Clin Immunol 2009, 123:510-511.
91. Chakravarty S.D., Yee A.F., Paget S.A. Rituximab successfully treats refractory chronic autoimmune urticaria caused by IgE receptor autoantibodies. JAllergy Clin Immunol 2011, 128:1354-1355.
92. Mallipeddi R., Grattan C.E. Lack of response of severe steroid-dependent chronic urticaria to rituximab. Clin Exp Dermatol 2007, 32:333-334.
93. Asero R., Tedeschi A., Coppola R., et al. Activation of the tissue factor pathway of blood coagulation in patients with chronic urticaria. JAllergy Clin Immunol 2007, 119:705-710.
94. Asero R., Tedeschi A., Riboldi P., et al. Severe chronic urticaria is associated with elevated plasma levels of D-dimer. Allergy 2008, 63:176-180.
95. Takeda T., Sakurai Y., Takahagi S., et al. Increase of coagulation potential in chronic spontaneous urticaria. Allergy 2011, 66:428-433.
96. Cugno M., Marzano A.V., Tedeschi A., et al. Expression of tissue factor by eosinophils in patients with chronic urticaria. Int Arch Allergy Immunol 2009, 148:170-174.
97. Khalaf A.T., Liu X.M., Sheng W.X., et al. Efficacy and safety of desloratadine combined with dipyridamole in the treatment of chronic urticaria. JEur Acad Dermatol Venereol 2008, 22:487-492.
98. Parslew R., Pryce D., Ashworth J., et al. Warfarin treatment of chronic idiopathic urticaria and angio-oedema. Clin Exp Allergy 2000, 30:1161-1165.
99. Chua S.L., Gibbs S. Chronic urticaria responding to subcutaneous heparin sodium. Br J Dermatol 2005, 153:216-217.
100. Asero R., Tedeschi A., Cugno M. Heparin and tranexamic acid therapy may be effective in treatment-resistant chronic urticaria with elevated D-dimer: a pilot study. Int Arch Allergy Immunol 2010, 152:384-389.
101. Grattan C.E., Francis D.M., Slater N.G., et al. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992, 339:1078-1080.